Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q34809019)
Watch
English
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
4282825
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25440090%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
review article
1 reference
stated in
Europe PubMed Central
title
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
4282825
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25440090%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
main subject
antibody
1 reference
based on heuristic
inferred from title
immunotherapy
1 reference
based on heuristic
inferred from title
author
Amer Assal
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
4282825
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25440090%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
author name string
Kim C Ohaegbulam
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
4282825
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25440090%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
Eszter Lazar-Molnar
series ordinal
3
1 reference
stated in
Europe PubMed Central
PMC publication ID
4282825
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25440090%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
Yu Yao
series ordinal
4
1 reference
stated in
Europe PubMed Central
PMC publication ID
4282825
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25440090%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
Xingxing Zang
series ordinal
5
1 reference
stated in
Europe PubMed Central
PMC publication ID
4282825
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25440090%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
publication date
30 October 2014
1 reference
stated in
Europe PubMed Central
PMC publication ID
4282825
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25440090%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
published in
Trends in Molecular Medicine
1 reference
stated in
Europe PubMed Central
PMC publication ID
4282825
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25440090%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
volume
21
1 reference
stated in
Europe PubMed Central
PMC publication ID
4282825
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25440090%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
issue
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
4282825
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25440090%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
page(s)
24-33
1 reference
stated in
Europe PubMed Central
PMC publication ID
4282825
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25440090%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
cites work
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
B cell responses to HIV antigen are a potent correlate of viremia in HIV-1 infection and improve with PD-1 blockade
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Nivolumab plus ipilimumab in advanced melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Structure and Interactions of the Human Programmed Cell Death 1 Receptor
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
PD-1 is a novel regulator of human B-cell activation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
T cell exhaustion
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
The PD-1 pathway in tolerance and autoimmunity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
PD-1 and its ligands in tolerance and immunity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
The B7 family and cancer therapy: costimulation and coinhibition
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Restoring function in exhausted CD8 T cells during chronic viral infection
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Activation of human lymphocytes by a monoclonal antibody to B lymphoblastoid cells; molecular mass and distribution of binding protein
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
8 July 2018
PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
26 October 2018
Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
26 October 2018
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
26 October 2018
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
26 October 2018
Structural and functional analysis of the costimulatory receptor programmed death-1.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4282825
retrieved
26 October 2018
Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25440090
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25440090
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25440090
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25440090
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1016/J.MOLMED.2014.10.009
1 reference
stated in
Europe PubMed Central
PMC publication ID
4282825
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25440090%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
PMC publication ID
4282825
1 reference
stated in
Europe PubMed Central
PMC publication ID
4282825
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25440090%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
PubMed publication ID
25440090
1 reference
stated in
Europe PubMed Central
PMC publication ID
4282825
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25440090%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
ResearchGate publication ID
268751845
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit